Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.53
Bid: 1.53
Ask: 1.60
Change: -0.002 (-0.13%)
Spread: 0.07 (4.575%)
Open: 1.53
High: 1.53
Low: 1.53
Prev. Close: 1.567
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 May 2021 11:15

RNS Number : 0553A
Hemogenyx Pharmaceuticals PLC
27 May 2021
 

27 May 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

TR-1 Standard form for notification of major holdings

 

Issuer Details

ISIN

GB00BYX3WZ24

Issuer Name

HEMOGENYX PHARMACEUTICALS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting

3. Details of person subject to the notification obligation

Name

Alexis Sandler

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

26-May-2021

6. Date on which Issuer notified

26-May-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.660000

0.000000

7.660000

75090685

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYX3WZ24

75090685

7.660000

Sub Total 8.A

75090685

7.660000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

 

13. Place Of Completion

London

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUBARRARUVUAR
Date   Source Headline
9th Mar 20212:00 pmRNSPrice Monitoring Extension
9th Mar 202111:00 amRNSPrice Monitoring Extension
9th Mar 20217:00 amRNSDirector/PDMR Shareholding
8th Mar 20217:00 amRNSH.C. Wainwright Investment Conference
3rd Mar 20217:00 amRNSHEMO-CAR-T Update
26th Feb 202110:05 amRNSTotal Voting Rights
25th Feb 20214:56 pmRNSConversion of Convertible Loan Notes
15th Feb 20214:41 pmRNSSecond Price Monitoring Extn
15th Feb 20214:36 pmRNSPrice Monitoring Extension
10th Feb 20217:00 amRNSAllotment of Shares
3rd Feb 20217:01 amRNSDraw Down Under Financing Facility Agreement
29th Jan 20212:24 pmRNSPublication of Prospectus
13th Jan 20217:00 amRNSUpdate on CDX Antibody Development
6th Jan 20213:53 pmRNSResult of General Meeting
5th Jan 20217:00 amRNSCAR-T Master Translational Agreement with Penn
8th Dec 20207:00 amRNSChange to Date of General Meeting
2nd Dec 20204:41 pmRNSSecond Price Monitoring Extn
2nd Dec 20204:36 pmRNSPrice Monitoring Extension
2nd Dec 202011:06 amRNSSecond Price Monitoring Extn
2nd Dec 202011:01 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSPosting of Circular
18th Nov 20204:41 pmRNSSecond Price Monitoring Extn
18th Nov 20204:36 pmRNSPrice Monitoring Extension
18th Nov 20202:06 pmRNSSecond Price Monitoring Extn
18th Nov 20202:01 pmRNSPrice Monitoring Extension
18th Nov 202010:39 amRNSFinancing Facility of up to £60 Million
27th Oct 20207:00 amRNSCDX Development Agreement Further Extension
19th Oct 20207:00 amRNSPresentation at the American Society of Hematology
6th Oct 20207:00 amRNSSAFE-HEMO-CAR-T Effective against AML in vitro
30th Sep 20207:00 amRNSInterim Results for the period ended 30 June 2020
22nd Sep 202012:52 pmRNSFurther re. Grant of Options
10th Sep 20204:40 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
26th Aug 20202:06 pmRNSSecond Price Monitoring Extn
26th Aug 20202:00 pmRNSPrice Monitoring Extension
25th Aug 20204:40 pmRNSSecond Price Monitoring Extn
25th Aug 20204:35 pmRNSPrice Monitoring Extension
21st Aug 20209:52 amRNSGrant of Options
14th Aug 20207:00 amRNSPresentations at Cancer Immunotherapy Symposia
11th Aug 20207:00 amRNSCAR-T Agreement with University of Pennsylvania
31st Jul 20207:00 amRNSBroker's Research Note
20th Jul 20204:40 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
20th Jul 20202:05 pmRNSSecond Price Monitoring Extn
20th Jul 20202:00 pmRNSPrice Monitoring Extension
14th Jul 202011:00 amRNSPrice Monitoring Extension
14th Jul 20209:06 amRNSSecond Price Monitoring Extn
14th Jul 20209:00 amRNSPrice Monitoring Extension
13th Jul 20204:36 pmRNSPrice Monitoring Extension
13th Jul 20203:16 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.